InViragen Initiates Phase 1 Study of Hand, Foot and Mouth Disease Vaccine in Singapore
6/16/2011 8:46:43 AM
SINGAPORE--(BUSINESS WIRE)--Inviragen announced today the initiation of the first clinical trial of the Company’s proprietary Hand, Foot and Mouth Disease (HFMD) investigational vaccine, INV21, a highly purified virus particle preparation designed to protect against HFMD caused by enterovirus 71 (EV71). The study will be conducted in Singapore at the Investigational Medicine Unit at the National University Health System under Inviragen’s memorandum of understanding with the Duke-NUS Graduate Medical School. This Phase 1 clinical trial of INV21 will assess the safety of the vaccine as well as immune responses in healthy adult volunteers.
comments powered by